Sanofi said it will pay MannKind as much as $925 million for the global rights to inhaled insulin Afrezza, just a couple months after the treatment received FDA approval. Afrezza is the world's only inhaled insulin, an alternative to injections for adults with diabetes. MannKind will receive an upfront payment of $150 million and milestone payments of up to $775 million, depending on the drug's commercial success. Sanofi and MannKind will share profits and losses on a global basis, with Sanofi retaining 65% and MannKind receiving 35%. Sanofi said the deal is the latest opportunity for the company to bring another insulin option to people with diabetes around the globe.

More from Video

There's Still Time To Invest - Here and Abroad

There's Still Time To Invest - Here and Abroad

Turkey: How it Affects our Dollar, Other Countries and Your 401(k) (Listen!)

Turkey: How it Affects our Dollar, Other Countries and Your 401(k) (Listen!)

Gold's Beating May Be Nearing an End - Bloomberg Intelligence

Gold's Beating May Be Nearing an End - Bloomberg Intelligence

Rewind: Jim Cramer on Turkey, Deutsche Bank and Amazon's Advertising Strength

Rewind: Jim Cramer on Turkey, Deutsche Bank and Amazon's Advertising Strength

Market Madness: Are You Worried About a Bear Market or Retail Earnings?

Market Madness: Are You Worried About a Bear Market or Retail Earnings?